title: Psoriasis treatments by payment type in the US outpatient office setting.
abstract: BACKGROUND
  Many factors, including patients' methods of payment, may influence psoriasis treatment decisions.
  
  
  OBJECTIVE
  To characterize psoriasis treatments by patients' types of payment in the US outpatient office setting.
  
  
  METHODS
  Using the National Ambulatory Medical Care Survey (NAMCS), a large survey that samples outpatient office visits to US non-federally funded physicians, visits linked with sole diagnoses for psoriasis (ICD-9-CM: 696.1) were identified. There were 545 unweighted records. The types and number of treatments prescribed at these visits were categorized by expected major payment type to be used for the visit.
  
  
  RESULTS
  Mainstay psoriasis therapies such as vitamin D analogs and clobetasol were prescribed regardless of payment type. Retinoids were also within the most frequently prescribed psoriasis medications for all payment types, however they were less frequently prescribed than vitamin D analogs. Payment type did not have a significant effect on the number of medications prescribed at psoriasis visits.
  
  
  CONCLUSIONS
  Data on treatment adherence and filling of prescriptions are not included in the NAMCS database.
  
  
  CONCLUSIONS
  Prescribing patterns for psoriasis medications are similar across payment type. Additional factors appear to modulate therapy choice for patients with psoriasis.
authors.forename: Kenyatta
authors.initials: K
authors.lastname: Mireku
authors.forename: Karen E
authors.initials: KE
authors.lastname: Huang
authors.forename: Swetha
authors.initials: S
authors.lastname: Narahari
authors.forename: Scott A
authors.initials: SA
authors.lastname: Davis
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002990:Clobetasol / Q000627:therapeutic use; D004363:Drug Utilization / Q000706:statistics & numerical data; D019538:Health Care Surveys; D006801:Humans; D007348:Insurance, Health; D008297:Male; D008484:Medicaid; D006278:Medicare; D008875:Middle Aged; D010045:Outpatients; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D012176:Retinoids / Q000627:therapeutic use; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D012176:Retinoids; D014815:Vitamins; D014807:Vitamin D; D002990:Clobetasol; D014222:Triamcinolone Acetonide